Loading clinical trials...

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Fuzheng Huayu Tablets Against Posthepatitic Cirrhosis

NCT00543426•Shanghai University of Traditional Chinese Medicine

Summary

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM). The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of B Post hepatitic cirrhosis.
•Male or female patients between 18\~65 years old.
•Written informed consent.

Exclusion Criteria

•Child-Pugh C above 12, or ALT \> 2×ULN, TBiL \> 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.
•Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.
•Deformed man by the law.
•Pregnancy or breast feeding women, or unwilling to have contraception.
•Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.
•Enter other trials lately one month.
•Other cause of cirrhosis.

Locations (1)

Shuguang Hospital

Shanghai, China

Key Dates

Start Date

September 1, 2007

Primary Completion Date

May 1, 2009

Completion Date

June 1, 2009

Last Updated

March 7, 2013

Enrollment

200

ACTUAL participants

Conditions

Posthepatitic Cirrhosis

Interventions

Fuzheng Huayu Tablets

DRUG

sham Fuzheng Huayu Tablets (placebo)

DRUG